These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28374559)

  • 1. Incorporating thyroid markers in Down syndrome screening protocols.
    Dhaifalah I; Salek T; Langova D; Cuckle H
    Prenat Diagn; 2017 May; 37(5):510-514. PubMed ID: 28374559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA.
    Johnson J; Pastuck M; Metcalfe A; Connors G; Krause R; Wilson D; Cuckle H
    Prenat Diagn; 2013 Nov; 33(11):1044-9. PubMed ID: 23836291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-free fetal DNA analysis in maternal plasma as screening test for trisomies 21, 18 and 13 in twin pregnancy.
    Le Conte G; Letourneau A; Jani J; Kleinfinger P; Lohmann L; Costa JM; Benachi A
    Ultrasound Obstet Gynecol; 2018 Sep; 52(3):318-324. PubMed ID: 28833712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical strategies in contingent sequential screening for Down syndrome.
    Benn P; Wright D; Cuckle H
    Prenat Diagn; 2005 Aug; 25(8):645-52. PubMed ID: 16049988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining first and second trimester markers for Down syndrome screening: think twice.
    Cocciolone R; Brameld K; O'Leary P; Haan E; Muller P; Shand K
    Aust N Z J Obstet Gynaecol; 2008 Oct; 48(5):492-500. PubMed ID: 19032666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First- and second-trimester evaluation of risk for Down syndrome.
    Ball RH; Caughey AB; Malone FD; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Emig D; D'Alton ME;
    Obstet Gynecol; 2007 Jul; 110(1):10-7. PubMed ID: 17601890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D; Langlois S; Douglas Wilson R; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A unified approach to risk assessment for fetal aneuploidies.
    Wright D; Wright A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):48-54. PubMed ID: 25315809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
    Nicolaides KH; Wright D; Poon LC; Syngelaki A; Gil MM
    Ultrasound Obstet Gynecol; 2013 Jul; 42(1):41-50. PubMed ID: 23744626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening.
    Wright D; Bradbury I; Benn P; Cuckle H; Ritchie K
    Prenat Diagn; 2004 Oct; 24(10):762-6. PubMed ID: 15503281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations on prenatal screening and the connections to other diseases such as thyroid dysfunction.
    Springer D; Potlukova E; Limanova Z; Zima T
    Clin Chem Lab Med; 2012 Mar; 50(7):1211-20. PubMed ID: 22850054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling Down syndrome screening performance using first-trimester serum markers.
    Koster MP; Wortelboer EJ; Stoutenbeek P; Visser GH; Schielen PC
    Ultrasound Obstet Gynecol; 2011 Aug; 38(2):134-9. PubMed ID: 21800388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting the result of additional second-trimester markers from a woman's first-trimester marker profile: a new concept in Down syndrome screening.
    Maymon R; Cuckle H; Jones R; Reish O; Sharony R; Herman A
    Prenat Diagn; 2005 Dec; 25(12):1102-6. PubMed ID: 16231324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-free DNA and contingent screening: Our first year.
    Gomes HH; Lourenço I; Ribeiro J; Martins D; Ribeiro R; Francisco C
    J Gynecol Obstet Hum Reprod; 2019 Sep; 48(7):509-514. PubMed ID: 30951890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to interpret thyroid function tests.
    Koulouri O; Gurnell M
    Clin Med (Lond); 2013 Jun; 13(3):282-6. PubMed ID: 23760704
    [No Abstract]   [Full Text] [Related]  

  • 16. Cross-trimester repeated measures testing for Down's syndrome screening: an assessment.
    Wright D; Bradbury I; Malone F; D'Alton M; Summers A; Huang T; Ball S; Baker A; Nix B; Aitken D; Crossley J; Cuckle H; Spencer K
    Health Technol Assess; 2010 Jul; 14(33):1-80. PubMed ID: 20624355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential and contingent prenatal screening for Down syndrome.
    Wald NJ; Rudnicka AR; Bestwick JP
    Prenat Diagn; 2006 Sep; 26(9):769-77. PubMed ID: 16821246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study.
    Audibert F; Dommergues M; Benattar C; Taieb J; Thalabard JC; Frydman R
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):26-31. PubMed ID: 11489221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal cfDNA screening for Down syndrome--a cost sensitivity analysis.
    Cuckle H; Benn P; Pergament E
    Prenat Diagn; 2013 Jul; 33(7):636-42. PubMed ID: 23674341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive view and increased likely uptake of follow-up testing with analysis of cell-free fetal DNA as alternative to invasive testing among Danish pregnant women.
    Miltoft CB; Rode L; Tabor A
    Acta Obstet Gynecol Scand; 2018 May; 97(5):577-586. PubMed ID: 29350746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.